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875relate their observation that Holter abnormalities
typically precede structural ﬁndings on imaging. In
our clinical practice, and borne out by the data from
our study, pediatric patients rarely fulﬁll the major
criterion for arrhythmias. Arrhythmias as a minor
criterion were more prevalent but did not distin-
guish between the different diagnostic certainty
groups.
Dr. te Riele and colleagues highlight that at the
time of data collection, only 49 of 142 patients had
undergone genetic testing. Despite the undisputed
value of genetic testing both within and outside of the
Task Force Criteria, important limitations of genetic
testing must be recognized: up to 50% of ARVC pa-
tients are gene-elusive, and 30% to 40% of gene-
positive patients remain nonpenetrant well into
adulthood (5). Thus, at present, the presence of an
ARVC mutation cannot provide an alternate standard
for the presence of ARVC disease.
Once again, we would like to thank Dr. te Riele
and colleagues for their critical review of our work
and for highlighting important areas for future
research. In a disease that contributes signiﬁcantly
to pediatric and young adult sudden death, and
which, once established in the adult, is likely difﬁ-
cult to reverse, improvements in pediatric diagnosis
will be paramount.*Lars Grosse-Wortmann, MD
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With Prosthetic Valve
Thrombosis After Failed
Thrombolytic TherapyWe would like to comment on the recent article by
Karthikeyan et al. (1), which reports the outcome of
oral anticoagulation in patients followed-up after
failure or partial response to thrombolytic therapy
(TT) for prosthetic valve thrombosis (PVT). Although
we appreciate the authors’ work because they
specify important data regarding the follow-up of
PVT patients after TT for the ﬁrst time, there remain
some major drawbacks to be addressed.
The statement that about one-third of the patients
treated with TT do not have successful restoration of
valve function is not comparable with the most recent
evidence reporting success rates of >85% in patients
with PVT (2–5). Moreover, they argue that surgery is
more effective than TT, which contradicts the data
reported in the most recent meta-analysis by Castilho
et al. (5). Clinicians should be cautious of over-
emphasizing the efﬁcacy of surgery over TT for PVT,
unless the results of randomized and controlled
trials are available. We are currently conducting a
randomized controlled trial (NCT02243839), a head-
to-head comparison of outcomes of TT and surgery,
which we feel will provide invaluable data in this
regard.
Complete normalization of valve leaﬂet motion on
ﬂuoroscopy and valve gradients on echocardiography
may not be a sure sign of complete normalization of
valve function. Such patients may still have a signif-
icant but “Doppler silent” thrombus burden requiring
further treatment with TT, because the risk of
reobstruction or embolism continues. As the authors
report, reduction in valve gradients may not be
associated with the occurrence of adverse outcomes.
The use of serial transesophageal echocardiography
(TEE) is indispensable for quantitative visualization
of thrombus burden in patients with PVT. Hence, TEE
should play a central role in every step of manage-
ment in patients with PVT, including the initial
diagnosis, guidance of therapy, evaluation of the
outcome, and identiﬁcation of patients who are at
high risk of adverse events.
In the current study, the authors report 31
eligible patients of 122 patients undergoing TT. This
means a 74.6% TT success rate at most, which is
relatively low compared with current evidence (2–5).
This may be caused by the type of TT agents or
protocols used in the current study. We have
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876previously reported that repeated doses of low-dose
(25 mg) and slow infusion (6 h) alteplase under the
guidance of serial TEE was superior to faster infu-
sion and/or higher dose protocols or streptokinase
(2). This protocol provided favorable results even
in pregnant patients with PVT (3). In addition, we
have very recently reported that ultra-slow (25 h)
infusion of low-dose (25 mg) alteplase without bolus
appears to be associated with quite low complica-
tions and mortality for PVT patients without
compromising post-thrombolytic success, except
for those with New York Heart Association func-
tional class IV. The TT success rate was 90% in this
study (4).
We agree with the authors that the rate of adverse
events is high in PVT patients followed with oral anti-
coagulation after failed TT. Although the improvement
of New York Heart Association functional class at least
1 step was associated with lower major complication
rates, the number of patients is too small to draw
a conclusion that reoperation may be delayed in
these patients. We believe that reserving oral anti-
coagulation only for those with nonobstructive left-
sided PVT who are not candidates for TT or residual
small thrombi after TT may be a more plausible stra-
tegy. We are currently conducting a randomized
controlled trial comparing the efﬁcacy and safety
outcomes of 3 different treatment strategies, including
intensiﬁed warfarin only, warfarin plus 100 mg ace-
tylsalicylic acid, and warfarin plus 300 mg acetylsali-
cylic acid (NCT02240953), which we believe will
clarify the uncertainty in the management of pa-
tients with nonobstructive PVT.
Consequently, PVT patients with spontaneous
normalization of valve gradients may still be at risk ofadverse events due to residual thrombus burden,
which only may be assessed by serial TEE. Hence,
referral to surgery should not be delayed with the
expectation of spontaneous valve opening in such
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